Lobbying Relationship

Client

Amgen U.S.A. Inc

More records

Lobbying firm

The Raben Group

More records

  • Lobbying in Support of HR 1548 the Pathways for Biologics Act, to promote patient safety while supporting the development of biologics.

Duration: to

General Issues: Science/Technology

Spending: about $365,000 (But it's complicated. Here's why.)

Agencies lobbied since 2009: House of Representatives, U.S. Senate, White House Office

Bills mentioned

H.R.1548: Pathway for Biosimilars Act

Sponsor: Anna G. Eshoo (D-Calif.)

S.726: Promoting Innovation and Access to Life-Saving Medicine Act

Sponsor: Charles E. Schumer (D-N.Y.)

Show All Mentioned Bills

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist Covered positions?
Robert Raben Asst. Attorney Gen, DOJ; Counsel House Judiciary
Meaghan Hohl Legis. Aide Sen. Kerry; Legis. Asst. Congr Watson
Larry Gonzalez n/a
Licy Do Canto n/a
Lawrence Gonzalez n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

Termination
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Registration

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print Google News logo Google_NewsInitiative_Lockup_FullColor RSS Search Search Twitter WhatsApp Resolving differences Check Building Arrow right Info circle Oops OOPS Pencil File text Bars Search Close Cogs Filter Compare Revolving Door Info card Activity Member menu Globe Document External link Quote News Calendar No Vote
Current site Current page